Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study.
<h4>Purpose</h4>The objective of this study was to characterize the demographic and clinical profile of RRMS patients receiving fingolimod in Spain, and to evaluate drug effectiveness and safety in clinical practice.<h4>Methods</h4>This observational, retrospective, multicent...
Main Authors: | Francisco Barrero, Javier Mallada-Frechin, María Luisa Martínez-Ginés, María Eugenia Marzo, Virginia Meca-Lallana, Guillermo Izquierdo, José Ramón Ara, Celia Oreja-Guevara, José Meca-Lallana, Lucía Forero, Irene Sánchez-Vera, María José Moreno, in representation of the MS NEXT study investigators |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2020-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0230846 |
Similar Items
-
Fingolimod for the Treatment of Relapsing-Remitting Multiple Sclerosis
by: Burcu Altunrende, et al.
Published: (2017-12-01) -
Psychometric Properties of the SymptoMScreen Questionnaire in a Mild Disability Population of Patients with Relapsing–Remitting Multiple Sclerosis: Quantifying the Patient’s Perspective
by: José Meca-Lallana, et al.
Published: (2020-01-01) -
The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study.
by: Guillermo Izquierdo, et al.
Published: (2017-01-01) -
Safety and Efficacy of Fingolimod in Iranian Patients with Relapsing-remitting Multiple Sclerosis
by: Fatemeh Yavari, et al.
Published: (2021-03-01) -
Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis
by: Gajofatto A, et al.
Published: (2015-12-01)